The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance

被引：38
|
作者：
Goette, Matthias [1 ,2 ,3 ]
机构：
[1] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada
[3] McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H3A 1A3, Canada
来源：
CURRENT OPINION IN VIROLOGY | 2012年 / 2卷 / 05期
基金：
加拿大健康研究院;
关键词：
HIV-1; REVERSE-TRANSCRIPTASE; CROSS-RESISTANCE; MUTATIONAL BIAS; NS5A INHIBITOR; VIRUS; PROTEASE; FIDELITY; REPLICATION; INFECTION; VARIANTS;
D O I：
10.1016/j.coviro.2012.08.004
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The selection of resistance to antiviral drugs depends on multiple parameters, including the genetic barrier that is often broadly defined as the number of mutations required to overcome drug selective pressure. In this review, it is intended to assess the roles of genetic barrier and viral fitness at various stages of the selection process. Several examples in the fields of HIV and HCV drug resistance show that the two parameters are distinct and independent. An analogy to the concept of kinetic versus thermodynamic control of chemical reactions supports a more narrow definition of the genetic barrier as the kinetic obstacle for the generation of genetic changes required to overcome selective pressure.
引用
收藏
页码：644 / 650
页数：7
相关论文
共 50 条
  • [11] Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development
    Svicher, Valentina
    Cento, Valeria
    Salpini, Romina
    Mercurio, Fabio
    Fraune, Maria
    Beggel, Bastian
    Han, Yue
    Gori, Caterina
    Wittkop, Linda
    Bertoli, Ada
    Micheli, Valeria
    Gubertini, Guido
    Longo, Roberta
    Romano, Sara
    Visca, Michela
    Gallinaro, Valentina
    Marino, Nicoletta
    Mazzotta, Francesco
    De Sanctis, Giuseppe Maria
    Fleury, Herve
    Trimoulet, Pascale
    Angelico, Mario
    Cappiello, Giuseppina
    Zhang, Xin Xin
    Verheyen, Jens
    Ceccherini-Silberstein, Francesca
    Perno, Carlo Federico
    DIGESTIVE AND LIVER DISEASE, 2011, 43 (12) : 975 - 983
  • [12] GENETIC INSTABILITY IN THE DEVELOPMENT OF DRUG-RESISTANCE
    GOLDIE, JH
    COLDMAN, AJ
    SEMINARS IN ONCOLOGY, 1985, 12 (03) : 222 - 230
  • [13] ANTIVIRAL DRUG-RESISTANCE
    FIELD, HJ
    GOLDTHORPE, SE
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1989, 10 (08) : 333 - 337
  • [14] Drug Resistance in Antiviral Therapy
    Locarnini, Stephen
    Bowden, Scott
    CLINICS IN LIVER DISEASE, 2010, 14 (03) : 439 - +
  • [15] ANTIVIRAL DRUG-RESISTANCE
    COEN, DM
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 616 : 224 - 237
  • [16] Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers
    Ma, Chunlong
    Zhang, Jiantao
    Wang, Jun
    MOLECULAR PHARMACOLOGY, 2016, 90 (03) : 188 - 198
  • [17] Fitness from drug resistance
    Darren J. Burgess
    Nature Reviews Genetics, 2014, 15 : 64 - 64
  • [18] Molecular virology of hepatitis B virus and the development of antiviral drug resistance
    Locarnini, Stephen
    Omata, Masao
    LIVER INTERNATIONAL, 2006, 26 : 11 - 22
  • [19] Unplanned antiretroviral treatment interruptions, genetic barrier, and development of resistance
    Llibre, J. M.
    Young, B.
    HIV MEDICINE, 2014, 15 (04) : 193 - 195
  • [20] Barcoding Genetically Distinct Plasmodium falciparum Strains for Comparative Assessment of Fitness and Antimalarial Drug Resistance
    Carrasquilla, Manuela
    Drammeh, Ndey F.
    Rawat, Mukul
    Sanderson, Theo
    Zenonos, Zenon
    Rayner, Julian C.
    Lee, Marcus C. S.
    MBIO, 2022, 13 (05):
12345